GEMCITABINE ACTAVIS 200 MG/VIAL

Pays: Israël

Langue: anglais

Source: Ministry of Health

Ingrédients actifs:

GEMCITABINE 200 MG/VIAL

Disponible depuis:

DEVRIES & CO. LTD

Code ATC:

L01BC05

forme pharmaceutique:

POWDER FOR SOLUTION FOR INFUSION

Mode d'administration:

I.V

Fabriqué par:

ACTAVIS GROUP PTC ehf, ICELAND

Groupe thérapeutique:

GEMCITABINE

indications thérapeutiques:

Gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.Gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Gemcitabine monotherapy can be considered in elderly patients or those with performance status 2. Gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first-line therapy. Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherap

Date de l'autorisation:

2013-06-01